Table 3.
Results of subgroup analysis of OS.
| Subgroup | No. of studies | HR (95% CI) | P | Heterogeneity | Model | |
|---|---|---|---|---|---|---|
| I2 (%) | Ph | |||||
| Cancer type | ||||||
| Mixed | 4 | 2.03 (1.10–3.75) | .23 | 81 | 0.01 | Random |
| NMIBC | 2 | 1.42 (0.72–2.82) | .315 | 81.2 | 0.021 | Random |
| MIBC | 2 | 2.73 (0.54–13.77) | .224 | 88.2 | 0.004 | Random |
| Country | ||||||
| China | 4 | 2.99 (2.01–4.44) | <.001 | 39.4 | 0.175 | Fixed |
| Non-China | 4 | 1.23 (0.98–1.55) | .074 | 59.4 | 0.06 | Random |
| Sample size | ||||||
| >1000 | 2 | 1.12 (1.03–1.22) | .007 | 0 | 0.561 | Fixed |
| <1000 | 6 | 2.47 (1.61–3.78) | <.001 | 52.9 | 0.059 | Random |
| Cut-off | ||||||
| ≥507 | 5 | 2.34 (1.13–4.83) | .022 | 81.5 | <0.001 | Random |
| <507 | 2 | 2.10 (1.48–2.98) | <.001 | 0 | 0.996 | Fixed |
| NR | 1 | 1.13 (1.03–1.23) | .006 | – | – | – |
| NOS | ||||||
| 8 | 3 | 4.56 (2.53–8.2) | <.001 | 0 | 0.515 | Fixed |
| 9 | 5 | 1.35 (1.04–1.74) | .021 | 67.3 | 0.016 | Random |
95% CI = 95% confidence interval, HR = hazard ratio, MIBC = muscle invasive bladder cancer, NOS = Newcastle-Ottawa Scale, NMIBC = non-muscle invasive bladder cancer, NR = not reported, OS = overall survival.